CYTHW 0.15 Cyclo Therapeutics, Inc.
| Range: | 0.05-0.37 | Vol Avg: | 832 | Last Div: | 0 | Changes: | -0.09 |
| Beta: | -0.38 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Dec 18 2020 | Empoloyees: | 8 | ||
| CUSIP: | 23254X110 | CIK: | 0000922247 | ISIN: | US23254X1101 | Country: | US |
| CEO: | Mr. N. Scott Fine | Website: | https://www.cyclotherapeutics.com | ||||
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow